EyePoint announces public offering pricing

EyePoint Pharmaceuticals is offering 10,526,500 shares of its common stock at $1.90 per share, the company announced in a press release.
Gross proceeds from the public offering are expected to be approximately $20 million, and the company granted the underwriters a 30-day option to purchase up to an additional 1,578,975 shares, the release said.
Net proceeds will be used to fund the commercialization of Dexycu (dexamethasone intraocular suspension 9%) and Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg).
The offer is expected to close on or about April 1.

Full Story →